XBiotech (XBIT) Competitors $2.85 -0.05 (-1.72%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.85 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIT vs. GLUE, RNAC, FHTX, RCKT, INBX, ABEO, AVIR, ALT, ALLO, and ADCTShould you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Abeona Therapeutics (ABEO), Atea Pharmaceuticals (AVIR), Altimmune (ALT), Allogene Therapeutics (ALLO), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. XBiotech vs. Its Competitors Monte Rosa Therapeutics Cartesian Therapeutics Foghorn Therapeutics Rocket Pharmaceuticals Inhibrx Biosciences Abeona Therapeutics Atea Pharmaceuticals Altimmune Allogene Therapeutics ADC Therapeutics XBiotech (NASDAQ:XBIT) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Which has more volatility and risk, XBIT or GLUE? XBiotech has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Do analysts rate XBIT or GLUE? Monte Rosa Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 220.11%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is XBIT or GLUE more profitable? Monte Rosa Therapeutics has a net margin of 3.86% compared to XBiotech's net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 2.65% beat XBiotech's return on equity.Company Net Margins Return on Equity Return on Assets XBiotechN/A -21.14% -19.55% Monte Rosa Therapeutics 3.86%2.65%1.65% Which has preferable earnings and valuation, XBIT or GLUE? XBiotech has higher earnings, but lower revenue than Monte Rosa Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXBiotech$4.01M21.67-$38.53M-$1.29-2.21Monte Rosa Therapeutics$75.62M3.90-$72.70M$0.0859.88 Does the media refer more to XBIT or GLUE? In the previous week, XBiotech had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 3 mentions for XBiotech and 0 mentions for Monte Rosa Therapeutics. XBiotech's average media sentiment score of 0.57 beat Monte Rosa Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media. Company Overall Sentiment XBiotech Positive Monte Rosa Therapeutics Neutral Do institutionals and insiders believe in XBIT or GLUE? 55.7% of XBiotech shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMonte Rosa Therapeutics beats XBiotech on 11 of the 16 factors compared between the two stocks. Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIT vs. The Competition Export to ExcelMetricXBiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.41M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-2.2117.7428.8623.83Price / Sales21.67178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book0.488.508.275.54Net Income-$38.53M-$55.06M$3.25B$259.28M7 Day Performance-0.70%-3.99%-3.73%-4.68%1 Month Performance-11.49%9.58%4.29%4.36%1 Year Performance-57.46%6.70%25.87%17.89% XBiotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBITXBiotech0.9764 of 5 stars$2.85-1.7%N/A-61.0%$88.41M$4.01M-2.21100News CoveragePositive NewsShort Interest ↑GLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.55-2.1%$15.33+176.3%+9.6%$348.76M$75.62M69.3890RNACCartesian Therapeutics1.4107 of 5 stars$13.70+2.8%$40.00+192.0%-20.3%$345.97M$38.91M-0.2664Upcoming EarningsFHTXFoghorn Therapeutics2.4956 of 5 stars$6.50+5.0%$12.13+86.5%-23.3%$345.04M$23.50M-4.78120Upcoming EarningsGap DownRCKTRocket Pharmaceuticals4.8355 of 5 stars$3.11-1.0%$17.87+474.5%-86.5%$335.31MN/A-1.18240Trending NewsUpcoming EarningsINBXInhibrx Biosciences1.3606 of 5 stars$24.57+6.5%N/A+48.2%$334.11M$200K0.21166ABEOAbeona Therapeutics3.8538 of 5 stars$6.62+1.4%$19.25+190.8%+34.9%$334.05M$3.50M-5.2190News CoverageAVIRAtea Pharmaceuticals1.6961 of 5 stars$3.79-2.8%$6.00+58.3%-4.4%$333.76MN/A-2.3070News CoverageUpcoming EarningsALTAltimmune2.2384 of 5 stars$4.03-1.2%$18.20+351.6%-40.7%$330.92M$20K-3.2050Upcoming EarningsALLOAllogene Therapeutics2.9848 of 5 stars$1.47-2.0%$8.44+474.5%-60.6%$328.10MN/A-1.20310News CoverageUpcoming EarningsADCTADC Therapeutics1.8537 of 5 stars$3.13-4.7%$7.75+148.0%-11.4%$325.30M$70.84M-2.16310News CoverageUpcoming Earnings Related Companies and Tools Related Companies GLUE Competitors RNAC Competitors FHTX Competitors RCKT Competitors INBX Competitors ABEO Competitors AVIR Competitors ALT Competitors ALLO Competitors ADCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
